Skip to main content

Advertisement

Table 1 Baseline clinical, pharmacological, and laboratory characteristics of study patientsa

From: N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial

  NAC group(n = 45) Placebo group(n = 45) P value
Baseline clinical characteristics    
   Age, years 63.25 ± 9.78 65.09 ± 9.40 0.45
   Sex (male/female) 20/25 34/11 0.005
   Body mass index, kg/m2 28.56 ± 4.81 27.85 ± 4.13 0.45
   Time since diagnosis of DM, years 10.11 ± 8.50 9.82 ± 7.57 0.86
   Systolic blood pressure, mmHg 156.05 ± 19.9 151.95 ± 18.4 0.34
   Diastolic blood pressure, mmHg 82.63 ± 7.60 81.22 ± 7.14 0.39
   Ejection fraction, % 49.45 ± 10.99 46.83 ± 14.15 0.37
Medications    
   Aspirin, n(%) 37(82.2%) 36(80%) 1.00
   ACE-inhibitors/ARB, n(%) 32(71.1%) 30(66.7%) 0.82
   β-blockers, n(%) 29(64.4%) 35(77.8%) 0.24
   Nitrates, n(%) 30(66.7%) 30(66.7%) 1.00
   Diuretics, n(%) 23(51.1%) 19(42.2%) 0.52
   Statins, n(%) 28(62.2%) 17(37.8%) 0.034
   Digitals, n(%) 6(13.3%) 6(13.3%) 1.00
Baseline laboratory values    
   Serum creatinine, mg/dL 1.736 ± 0.42 1.736 ± 0.17 1.00
   Serum urea nitrogen, mg/dL 60.56 ± 28.37 58.64 ± 28.94 0.75
   Creatinine clearance, mL/min 42.76 ± 11.97 43.97 ± 11.91 0.63
  1. a All plus-minus values are mean ± SD. DM, diabetes mellitus; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers.